Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Hospital Pharmacy Année : 2018

Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas

Stabilité à long terme du gel hydrophile à 0,1 % de rapamycine dans le traitement des angiofibromes faciaux

Résumé

Objectives : In recent years, various formulations containing rapamycin were tested, mainly with petrolatum to treat facial angiofibromas in tuberous sclerosis, especially in children. Nevertheless, a weak tolerance was found due to irritations and bleeding. Moreover, efficacy was insufficient in young adults. The aims of this study were to develop and characterize a hydro-alcoholic gel containing solubilized rapamycin, to realize the stability study at 4°C up to one year. Methods : Two different gels at 0.1% rapamycin were performed with or without α-tocopherol and urea. Different methods were used to characterize the gels: HPLC, gas chromatography, pH, visual observation and optical microscopy. A physicochemical and microbiological stability study was also conducted during 1 year at 4°C. Results : Whatever the formulation, gels were physicochemically and microbiologically stable up to 1 year at 4°C: Organoleptic characteristics and pH were unchanged, no significant decrease was found in rapamycin concentration, tocopherol droplets size was constant and the rheological comportment unmodified. Conclusions : The present study provides, for the first time, extended stability data concerning a hydro-alcoholic gel of rapamycin.
Fichier principal
Vignette du fichier
Article_VF.pdf (246.91 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03041293 , version 1 (04-12-2020)

Identifiants

Citer

Guillaume Le Guyader, Victoire Vieillard, Karine Andrieux, Mylène Rollo, Olivier Thirion, et al.. Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas. European Journal of Hospital Pharmacy, 2018, 27 (e1), pp.e48-e52. ⟨10.1136/ejhpharm-2018-001695⟩. ⟨hal-03041293⟩
43 Consultations
314 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More